Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism HSP stimulants(Heat-shock protein stimulants), PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), Insulin sensitizers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H22N4O2 |
InChIKeyMVLOQULXIYSERZ-UHFFFAOYSA-N |
CAS Registry66611-38-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | - | - | |
Muscular Dystrophy, Duchenne | Phase 2 | - | - | |
Beta Ketothiolase Deficiency | Phase 1 | US | 01 Oct 2010 | |
Beta Ketothiolase Deficiency | Phase 1 | HU | 01 Oct 2010 | |
Beta Ketothiolase Deficiency | Phase 1 | DE | 01 Oct 2010 | |
Chemotherapy-induced damage | Phase 1 | HU | - | |
COVID-19 | Preclinical | HU | - | 26 Mar 2021 |
Genetic Diseases, Inborn | Preclinical | US | 31 Oct 2020 | |
Tachycardia, Sinus | Preclinical | HU | - | 30 Sep 2020 |
Insulin Resistance | Preclinical | HU | 04 Apr 2006 |